Lifespan Cardiovascular Institute

Absorb III Patient

The purpose of this study is to assess the safety and effectiveness of treating blockages in the coronary (heart) arteries (blood vessels) with an investigational (experimental) device called Absorb™ Bioresorbable Vascular Scaffold (BVS) System (the “Absorb BVS”), compared to a commercially approved metallic stent coated with medication (drug-eluting stent) called XIENCE V® Everolimus Eluting Coronary Stent System.

XIENCE and Absorb BVS both use the drug everolimus. Everolimus helps to prevent the heart artery from re-narrowing. This re-narrowing is caused by re-growth of certain muscle cells inside the artery wall. Everolimus may stop cells in the artery wall from growing too much and therefore reduce the chance of artery re-narrowing.

The investigational device (study device) used in this study, Absorb BVS, is a temporary device which functions like a drug-eluting stent, but is not made out of metal. Instead it consists of a plastic scaffold made out of materials that over time will gradually break down and be resorbed into the artery wall leaving behind no permanent implant.

For more information, please contact:
Cardiovascular Research
The Miriam Hospital     
Lori-Ann DeSimone
Rhode Island Hospital
Cardiac Projects Office